KR20230051237A - 오토파지 활성화제 - Google Patents

오토파지 활성화제 Download PDF

Info

Publication number
KR20230051237A
KR20230051237A KR1020237008541A KR20237008541A KR20230051237A KR 20230051237 A KR20230051237 A KR 20230051237A KR 1020237008541 A KR1020237008541 A KR 1020237008541A KR 20237008541 A KR20237008541 A KR 20237008541A KR 20230051237 A KR20230051237 A KR 20230051237A
Authority
KR
South Korea
Prior art keywords
inositol
autophagy
salt
gene
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237008541A
Other languages
English (en)
Korean (ko)
Inventor
유코 나카가미
Original Assignee
가부시끼가이샤 레조낙
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시끼가이샤 레조낙 filed Critical 가부시끼가이샤 레조낙
Publication of KR20230051237A publication Critical patent/KR20230051237A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237008541A 2020-09-17 2021-09-17 오토파지 활성화제 Pending KR20230051237A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020156460 2020-09-17
JPJP-P-2020-156460 2020-09-17
PCT/JP2021/034305 WO2022059776A1 (ja) 2020-09-17 2021-09-17 オートファジー活性化剤

Publications (1)

Publication Number Publication Date
KR20230051237A true KR20230051237A (ko) 2023-04-17

Family

ID=80776143

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237008541A Pending KR20230051237A (ko) 2020-09-17 2021-09-17 오토파지 활성화제

Country Status (6)

Country Link
US (1) US20230364119A1 (https=)
EP (1) EP4215200A4 (https=)
JP (1) JPWO2022059776A1 (https=)
KR (1) KR20230051237A (https=)
CN (1) CN116600815A (https=)
WO (1) WO2022059776A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510902A (ja) 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2018080204A (ja) 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
WO2018173653A1 (ja) 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途
JP2019529514A (ja) 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944375A (ja) 1982-09-06 1984-03-12 Senjiyu Seiyaku Kk α−トコフエロ−ルリン酸エステルの安定な水溶液
US4654869A (en) 1985-09-11 1987-03-31 Itt Corporation Information collecting and forwarding apparatus
JPH0649715B2 (ja) 1987-02-10 1994-06-29 栗田工業株式会社 末端にイノシト−ル残基を結合したグルコオリゴ糖およびその製造方法
JPH0730066B2 (ja) 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
JP2747001B2 (ja) 1989-04-18 1998-05-06 昭和電工株式会社 Ｌ―アスコルビン酸―２―リン酸エステル類の製造法
JP2926412B2 (ja) 1989-05-19 1999-07-28 株式会社林原生物化学研究所 α―グリコシル―Ｌ―アスコルビン酸とその製造方法並びに用途
JPH05213763A (ja) * 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd 易吸収活性化カルシウム製剤
JPH06298783A (ja) 1993-03-31 1994-10-25 Mitsui Toatsu Chem Inc 新規なグリコシドの製造法
JP2705512B2 (ja) 1993-06-04 1998-01-28 昭和電工株式会社 Ｌ−アスコルビン酸−２−リン酸エステルの製造方法
JPH08134055A (ja) 1994-11-08 1996-05-28 Nippon High Potsukusu:Kk ３−ｏ−置換アスコルビン酸の製造方法
JPH0914705A (ja) 1995-06-29 1997-01-17 Hitachi Ltd 流体移送装置
GB9828565D0 (en) * 1998-12-23 1999-02-17 Rademacher Group Limited Inositol-containing hexasaccharidies,their synthesis and their uses
RU2309733C2 (ru) * 1999-08-20 2007-11-10 Ферросан А/С Фармацевтическая система доставки витамина с и витамина е и применение комбинации витаминов с и е для профилактики или лечения состояний, связанных с окислительной нагрузкой
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP4624831B2 (ja) * 2004-03-25 2011-02-02 昭和電工株式会社 イノシトール誘導体を含有する皮膚外用剤及び化粧料
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
EP3231804B1 (en) * 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
KR101021078B1 (ko) * 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
JP6312333B2 (ja) 2013-05-10 2018-04-18 昭和電工株式会社 糖化反応抑制剤
WO2016076310A1 (ja) 2014-11-10 2016-05-19 昭和電工株式会社 保湿剤
CN111051519B (zh) * 2017-09-04 2024-04-26 株式会社力森诺科 肌醇衍生物的混合物
JP2019112354A (ja) * 2017-12-25 2019-07-11 昭和電工株式会社 抗炎症剤及び抗炎症用組成物
JP2020156460A (ja) 2019-03-20 2020-10-01 株式会社リコー 液滴吐出装置用の液セット

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080204A (ja) 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
JP2018510902A (ja) 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2019529514A (ja) 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
WO2018173653A1 (ja) 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Aaron Barnett et al., Autophagy in Aging and Alzheimer's Disease: Pathologic or Protective?. J Alzheimers Dis. 2011; 25(3): 385-394.
Marta M. Lipinski et al., Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci USA. 2010, 107, 14164-14169.
Xiangqing Li et al., Cubeben induces autophagy via PI3K-AKT-mTOR pathway to protect primary neurons against amyloid beta in Alzheimer's disease. Cytotechnology (2019) 71: 679-686.
Yogendra S. Rajawat et al., Aging: Central role for autophagy and the lysosomal degradative system. Ageing Research Reviews 8 (2009) 199-213.
이노마타 외, 「오토파지와 노화의 관련성」, 기후켄 치과학회 잡지, 2018년, 제45권, 제1호, 1-7
카게야마 외, 「오토파지와 질환」, 영역 융합 리뷰, 2014년, 3, e006

Also Published As

Publication number Publication date
US20230364119A1 (en) 2023-11-16
JPWO2022059776A1 (https=) 2022-03-24
CN116600815A (zh) 2023-08-15
WO2022059776A1 (ja) 2022-03-24
EP4215200A4 (en) 2024-10-09
EP4215200A1 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
CN101111244B (zh) 含有山奈酚和槲皮素的透明质酸生成促进用组合物
US10918585B2 (en) Anti-aging agent and anti-aging composition for skin
JPWO2011093469A1 (ja) レドックス関連因子発現促進剤
JP6406636B2 (ja) 化粧料または皮膚外用剤
TWI790238B (zh) 含有葉黃素類或其鹽及菱屬植物加工物之腦之錐體細胞的減少抑制劑
KR20230054431A (ko) 오토파지 활성화제
KR20230051237A (ko) 오토파지 활성화제
JPH11323326A (ja) 活性酸素消去剤、皮膚保全剤および変色防止剤
JP6116869B2 (ja) 経口紫外線抵抗性向上剤
EP3636266A1 (en) Agent for inhibiting skin trouble and composition for inhibiting skin trouble
JP5703313B2 (ja) ３−ヒドロキシ−２−ピロンを含有する美白剤
KR20230051238A (ko) 오토파지 활성화제
TWI844795B (zh) 自噬活化劑
EP3777865A1 (en) Anti-aging composition
JPWO2018225728A1 (ja) グリコサミノグリカン産生促進剤及びグリコサミノグリカン産生促進用組成物
KR20170025370A (ko) 피부 개선용 조성물
JP2019112363A (ja) 制御性ｔ細胞分化抑制剤、及び免疫調節用組成物
HK40015380A (en) Composition for preventing and/or improving brain dysfunction comprising a lutein or salt thereof and a plant product of the genus trapa
KR20160064404A (ko) 파낙시돌을 함유하는 보습용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000